文献速递临床试验与 GCP真实世界研究与卫生经济

舒更葡糖或新斯的明预防腹部或胸部大手术后术后肺部并发症:SINFONIA随机对照优效性试验研究方案

Sugammadex or Neostigmine for prevention of post-operative pulmonary complications after major abdominal or thoracic surgery: study protocol for the SINFONIA (Sugammadex for preventioN oF pOst-operative pulmonary complIcAtions) randomised controlled superiority trial.
PubMed 文献 · Trials · 2025-08-28

SINFONIA是一项实用性、随机、开放标签、平行组优效性试验,含内部预试验,拟在英国约40个中心随机2500例50岁及以上接受腹部或非心脏胸部大手术的患者,比较舒更葡糖与新斯的明逆转神经肌肉阻滞的临床与成本效果。主要结局为30天存活且出院天数(DAH-30),关键次要结局包括术后肺部并发症发生率、生活质量和至180天死亡率,并嵌入观察性研究探讨舒更葡糖暴露后过敏致敏率。

要点

  • 术后肺部并发症是腹部和胸部大手术后重要致病和致死原因,神经肌肉阻滞药物使用是重要危险因素。
  • 与neostigmine相比,sugammadex逆转神经肌肉阻滞更迅速,小型临床疗效研究提示其可能与较低的术后肺部并发症发生率相关。
  • 两药在缩短住院时间或降低死亡率方面的比较临床有效性尚不确定,且sugammadex在广泛使用国家存在相对较高的危及生命的过敏反应发生率的安全性担忧。

核心结论

  • SINFONIA试验旨在回答麻醉医师和接受腹部及胸部大手术患者的重要问题,即舒更葡糖与新斯的明逆转神经肌肉阻滞对以患者为中心的结局(如DAH-30)、成本效果及过敏致敏发生率的影响。
  • 目前选择舒更葡糖还是新斯的明逆转神经肌肉阻滞在很大程度上取决于麻醉医师偏好,不断积累的证据提示舒更葡糖可能较新斯的明降低术后肺部并发症发生率。
  • 该实用性临床有效性试验将提供关于两药对DAH-30等以患者为中心的结局、成本效果及过敏致敏发生率影响的稳健证据。

研究设计与样本

  • SINFONIA是一项实用性、随机、开放标签、平行组、优效性试验,含内部预试验,比较舒更葡糖与新斯的明逆转神经肌肉阻滞的临床与成本效果。
  • 研究对象为50岁及以上接受腹部或非心脏胸部大手术的患者,计划从英国约40个中心随机2500例患者。
  • 主要结局为30天存活且出院天数(DAH-30),关键次要结局包括术后肺部并发症发生率、生活质量和至180天死亡率。
  • 嵌入观察性研究探讨舒更葡糖暴露后过敏致敏率。
  • 试验在招募开始前于ISRCTN数据库注册(注册号15109717)。

主要发现

  • 与neostigmine相比,sugammadex使用导致更快速的神经肌肉阻滞逆转,小型临床疗效研究提示其与较低的术后肺部并发症发生率相关。
  • 两药在减少住院时间或死亡率方面的比较临床有效性尚不确定。
  • sugammadex的潜在安全性担忧是在过去十年广泛使用该药物的国家中危及生命的过敏反应发生率相对较高。

关键数值与推荐

  • 主要结局为30天存活且出院天数(DAH-30)。
  • 关键次要结局包括术后肺部并发症发生率、生活质量和至180天死亡率。
  • 计划随机2500例患者,来自英国约40个中心。
  • 纳入年龄50岁及以上接受腹部或非心脏胸部大手术的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-operative pulmonary complications (PPCs) are an important source of morbidity and mortality after major abdominal and thoracic surgery. The use of neuromuscular blocking drugs in general anaesthesia is an important risk factor for PPCs. The incomplete reversal of this neuromuscular blockade at the end of surgery leads to residual weakness of respiratory muscles and predisposes to aspiration of pharyngeal contents, hypoventilation, and thus to PPCs such as atelectasis and pneumonia. Two reversal drugs for neuromuscular blocking agents are available: neostigmine and sugammadex. Compared with neostigmine, sugammadex use results in more rapid reversal of neuromuscular blockade, and small clinical efficacy studies have suggested an associated lower incidence of PPCs. The comparative clinical effectiveness of the two drugs in reducing length of hospital stay or mortality is uncertain. Moreover, a potential safety concern with sugammadex is the relatively high incidence of life-threatening allergic reactions in countries where this drug has been widely used over the last decade. METHODS: SINFONIA is a pragmatic, randomised, open-label, parallel group, superiority trial with an internal pilot which aims to compare the clinical and cost effectiveness of the two available drugs for reversal of neuromuscular blockade, sugammadex and neostigmine, in patients aged 50 years or older undergoing major abdominal or non-cardiac thoracic surgery. The trial will randomise 2500 patients from approximately 40 centres in the UK. The primary outcome will be days alive and out of hospital at 30 days (DAH-30), with key secondary outcomes of PPC incidence, quality of life, and mortality up to 180 days. An embedded observational study will investigate the rate of allergic sensitisation following exposure to sugammadex. DISCUSSION: The SINFONIA trial addresses an important question for anaesthetists and for patients undergoing major abdominal and thoracic surgery. The choice of reversal agent for neuromuscular blockade between sugammadex and neostigmine is currently largely a matter of anaesthetist preference. A growing body of evidence suggests that sugammadex may reduce the incidence of post-operative pulmonary complications relative to neostigmine. This pragmatic clinical effectiveness trial will provide robust evidence as to the effects of the two drugs on patient-centred outcomes such as DAH-30, as well as on cost effectiveness and the incidence of allergic sensitisation. TRIAL REGISTRATION: The trial was registered on the ISRCTN database ( https://www.isrctn.com ) prior to opening to recruitment (registration no 15109717).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Silversides JA, Savic L, Hiller L, et al. Sugammadex or Neostigmine for prevention of post-operative pulmonary complications after major abdominal or thoracic surgery: study protocol for the SINFONIA (Sugammadex for preventioN oF pOst-operative pulmonary complIcAtions) randomised controlled superiority trial. Trials. 2025. PMID: 40877881. doi:10.1186/s13063-025-08987-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。